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Summary 
The interleukin 2 receptor 0t (IL2Rcl; CD25; Tac) is the prototypic model for soluble receptor 
studies.  It exists in vivo as a transmembrane complete molecule (TM-Tac) on cell surfaces and 
as a truncated soluble form (sTac; slL2Rot), sTac has been used as a serum marker ofT cell acti- 
vation in immune disorders and of tumor burden in Tac-expressing malignancies.  In vivo, serum 
levels of all soluble proteins depend on the balance between production and catabolism, but lit- 
tle  is  known  about  the  metabolic  features  of this  class  of molecules.  We  have  developed  a 
model for Tac metabolism that incorporates new insights in its production and catabolism. Tac 
was shed from the surface of malignant and activated human T  cells with a modal half-life (tl/2) of 
2-6 h, but which was prolonged under certain circumstances. The rate of shedding is first order 
overall and nonsaturable  over a two order of magnitude range of substrate  (TM-Tac)  expres- 
sion. Once shed from cells, sTac is subject to catabolic activities in the host. In vivo studies in 
mice showed that 90% ofsTac was catabolized by the kidney with a h/2 of 1 h  and a filtration 
fraction of 0.11  relative to creatinine.  The remaining 10% of catabolism was mediated by other 
tissues  with a tl/2 of 10 h. Approximately 1-3% ofsTac is excreted intact as proteinuria with the 
remaining 97-99% catabolized to amino acids. Antibody to the receptor induced a marked de- 
lay in sTac catabolism by preventing filtration of the smaller protein through the renal glomeru- 
lus and additionally suppressing  other nonrenal catabolic mechanisms.  A  discrepancy between 
the catabolic rates for Tac and anti-Tac in the same complex was interpreted as a previously un- 
recognized differential  catabolic  mechanism,  suggesting features  of the  Brambell  hypothesis 
and immunoglobulin G  transport and catabolism, in which the antigen-in-complex in intracel- 
lular vesicles is relatively less protected from catabolism than the associated antibody.  In light of 
the pivotal role played by the kidney in sTac catabolism  and the impact of administered anti- 
body, the serum concentration of Tac in the settings of renal dysfunction or antibody therapy is 
not a suitable surrogate of activated T  cells or of the body burden of tumor. These results pro- 
vide parameters for assessing soluble receptor-ligand interactions generally. 
C 
ell  surface  receptors,  adhesion  molecules,  and  their 
shed soluble forms are increasingly the subject of bio- 
logical  and  clinical  investigations  (1,  2).  They are  widely 
evaluated for diagnosis and prognosis in human disease  (3), 
and as treatment targets or as therapeutic agents themselves 
(4,  5).  The  array  of surface  structures  generating  soluble 
forms is very large, tallied at 43 in a  1991  review (6),  with 
further molecules described since that time. Yet there is lit- 
tle data on the generation,  distribution,  and pharmacology 
of soluble receptors in general. 
The prototypic model for these receptors is the  IL2R ot 
chain.  It was among the first to be recognized as having a 
soluble  form,  and has  additionally been the  subject  of di- 
verse laboratory and  clinical investigations.  The full IL2R 
plays a central role in lymphocyte activation and prolifera- 
tion.  It is  comprised  of at least  three  chains  (or, [~,  ~/), of 
which the  ot chain  (IL2Rot; CD25),  termed  "Tac ''1 for T 
1Abbreviations used in his paper: ATL, adult T cell leukemia; CEA, carcino- 
embryonic antigen; GFR, glomerular filtration rate; S, substrate surface 
TM-Tac; ss, steady state; sTac, soluble Tac; TM-Tac,  transmembrane 
Tac; constants: k, Tac shedding rate constant; kmet, Tac metabolic rate 
constant; k,, renal component of kmet; knr, nonrenal component of kmet; 
k~e, kev, rate constants for vascular-to-extravascular and extravascular-to- 
vascular transport, respectively; q, Tac production rate constant; chemical 
species: A, anti-Tac; B, sTac; AB, monosaturated anti-Tac ]  Tac complex; 
AB  2, bisaturated anti-Tac {  Tac2 complex; A*, B*, AB  ~, A'B, A'B2, AB2*, 
radioactive components and their complexes. 
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not expressed  on resting lymphocytes but is markedly up- 
regulated with activation of T, B, and NK cells,  and mac- 
rophages. As such, it has been used as a target for antibodies 
and other immunodirected  therapies  that selectively attack 
activated  or malignant  Tac-expressing  cells  while  sparing 
the normal resting T  cell repertoire  (7).  The expression of 
this  molecule  has  been  extensively  investigated  from  the 
perspective of sigualing events, promoter regulation, mRNA 
transcription, and protein synthesis (8). 
The efferent part of Tac regulation--its  catabolism--has 
been less well characterized. Similar to other shed molecules, 
little is known except that the soluble form of Tac (sTac) is 
generated in an active proteolytic process against the mem- 
brane-bound form (9).  sTac levels have been suggested as 
surrogates of T  cell activation in autoimmune and allograft 
settings and as a measure of tumor burden in Tac-express- 
ing malignancies (10-15).  sTac can accumulate to present a 
significant antigen load that binds  administered  antibody or 
IL2 toxin in anti-IL21L therapies,  paralleling reports in anti- 
body therapies directed against lymphomas expressing B cell 
idiotypes (16), melanomas and neuroendocrine tumors ex- 
pressing gangliosides GD2 and GD3 (17,  18), and carcino- 
mas expressing carcinoembryonic antigen (CEA) (19). 
The serum level of sTac,  as with  all  proteins,  reflects  a 
balance between the rate of synthesis and release from cells 
and  the  fractional rate  of catabolism.  To  interpret  soluble 
receptor levels in disease  as a measure  of cellular synthesis, 
one must equally understand the pathophysiological factors 
that regulate  synthesis  and that  alter the  catabolism  of the 
protein.  Similarly,  the interaction with antibodies  or other 
antireceptor  molecules has  the potential  to perturb  this in 
vivo balance. Accordingly, several aspects of the regulation 
of soluble  receptor  were  examined,  sTac  production  was 
measured  from  Tac-expressing  human  cells  in  culture  to 
infer mechanisms of soluble receptor generation. Metabolic 
evaluations were performed in mice to derive pharmacoki- 
netic parameters and to assess the role of the kidney in ca- 
tabolism.  Finally, reciprocal studies examined the impact of 
soluble receptor-antibody interactions on catabolism to antic- 
ipate the iatrogenic impact of such therapeutic interventions. 
Materials and Methods 
Cells and Cell Lines 
Malignant  cells from patients  were harvested from blood on 
Ficoll-Hypaque. 2 ￿  106 cells were dispensed in 24-well plates in 
2 ml RPMI 1640 +  5% human AB serum.  Tac-expressing T cell 
line HUT102 was maintained in RPMI +  10% FCS. 
Surface Tac (Transmembrane-Tac)  and s Tac 
Viability  was  monitored  by  Trypan  blue  exclusion.  Trans- 
membrane  (TM)-Tac was  quantitated by 3H-anti-Tac antibody 
(gift of R. Kozak, NIH, Bethesda,  MD) binding modified from 
earlier  methods  (20). sTac  was determined by ELISA (21) by a 
commercial laboratory  (Hazleton Labs,  Vienna,  VA).  The  unit 
definition for sTac was "~  pg or 0.13 fmol. One evaluation era- 
ployed T  cell activation data from Jacques et al.  (22) in an assay 
closely parallel to our own. 
Derivation  of Tac Production Rate and SuoCace tl/2 
sTac  (B) production is modeled as a first order process  that is 
proportional to "substrate"  surface TM-Tac expression  (S): 
dB/dt  =  kS  (Eq. 1) 
For fixed cell numbers and changing TM-Tac (primary malignant 
cells), solution yields: 
AB  =  1/2kAt(S + So)  (Eq. 2) 
Where TM-Tac is constant and cell number is changing (cell line 
HUT102),  then 
AB  =  (k/c) S  O  (N 1 -  No)  (Eq. 3) 
in which c  =  In (N1/N0)/At. Where cell number and Tac/cell 
were varying (activated T cells), these methods were combined in 
a numerical solution (not shown). 
Proteins and Radiolabeling 
Recombinant human sTac  (gift ofJ.  Hakimi,  Hoffmann-La 
Roche, Nutley, NJ) was >95% pure by HPLC and SDS-PAGE 
(not shown). Nonspecific murine antibody UPC (IgG2a,  K) was 
obtained from Cappell Laboratories  (Cochranville,  PA). Proteins 
were labeled with 131I or 1251 to ~1-3 IxCi/Ixg as described  (20). 
Antibody bindability  was assayed as described  (20). 
Mice 
Nu/nu mice (Charles River Laboratories,  Wilmington, MA) at 
12-16  wk  of age  maintained  on  thyroid-blocking doses  of KI 
were injected with radioproteins by tail vein or intraperitoneally 
in 0.2 ml of 1% BSA in PBS.  Other animals were administered 
radioactivity  in  continuous  infusions  with  7-d  microosmotic 
pumps (Alzet, Palo Alto, CA) implanted subcutaneously. 
Assay of Protein Survival 
For rapidly  catabolized proteins,  or with  any protein  in ne- 
phrectomized or ureter-ligated animals that cannot eliminate  cat- 
abolic products, it is essential to assay protein-bound radioactivity 
instead of total radioactivity for pharmacokinetics.  Methods were 
modified from Wochner et al. (23). Blood samples were collected 
in  heparinized  glass capillaries  via  tail  vein,  counted,  and  cor- 
rected for protein-bound counts by TCA precipitation or by ex- 
clusion  chromatography  of representative  samples.  For  whole 
body catabolism, carcasses were individually  homogenized and al- 
iquots TCA-precipitated and processed. 
Pharmacokinetic Modeling 
Blood die-away curves of protein-associated counts were ana- 
lyzed as two compartment models (Schema 1) using numerical  in- 
tegration by pcNONLIN 4.0 (SCI Software, Lexington, KY), ex- 
cept as noted. For nephrectomized or ureter-ligated animals, the 
gradual  impact of uremia  made  it possible  only to do el-phase 
modeling, approximated as a first order system over the first 4--8 h 
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Relation of Renal Function to s Tac Levels 
sTac (B) concentration in vivo is modeled by zero order pro- 
duction (q) and first order loss (k~,~t) constants: 
dBIdt =  q -  kmetB  (Eq. 4) 
kme  t is composed of renal (k~) and nonrenal (knr) terms: 
krnet =  k  r + kr~  (Eq. 5) 
At steady state (ss), dB/dt =  0, and 
Bss  ~-  q/kme  t --~ q/(k r -~- knr  )  (Eq. 6) 
When renal filtration ofsTac is changed to a, the fraction of nor- 
mal glomerular filtration rate  (GFR),  then  the  new steady state 
Tac level, Bff, is increased by the fraction: 
Bss'/Bss  =  1 +  (1  -  (x)/[ci +  kffk,~]  (Eq. 7) 
=  1 +  ([3  -  1)/[1  + [3kr/knr  ]  (Eq. 8) 
in which [3, the serum creatinine, is inversely related to GFR. 
The filtration ratio is the ratio of Tac relative to creatinine filtered 
through the glomeruhis: 
FR  =  k~  *  ValGFR  (Eq. 9) 
GFR for mice is ~0.1  ml/min and the plasma volume is N1 
inl, which is taken as the volume of distribution,  Va, during the 
early time ([3-reduced) extrapolation (24). 
Experimental Model for Effect of Antibody on Catabolism 
Intravenous Bolus.  tLadiolabeled Tac (B*) or anti-Tac (A*) was 
administered alone or with excess unlabeled antibody or antigen. 
Radiolabeled UPC,  an isotype-matched, irrelevant mAb, was in- 
cluded as an internal control. Five mice were used in each group. 
The design of Expt. A2 ensures that antibody will saturate labeled 
Tac throughout  the experiment,  but the  excess of Tac in Expt. 
A4 saturates labeled anti-Tac only to 60 h by a two-compartment 
simulation (not shown). Accordingly, no statistics are reported for 
A4, which are derived in a more rigorous design in which unla- 
beled Tac  was  repeatedly injected intraperitoneally to  maintain 
continuous excess of antigen over antibody. I.p. injection of Tac 
regenerates the 4-5-h tl/2 of the serum and whole body [3-phase 
kinetics after i.v. injection, while avoiding the large (x-phase loss 
that accompanies i.v.  dosing. This  strategy follows that pursued 
by Chang et al. (25) to prolong IL2 survival. Tests of plasma con- 
firmed  >90%  saturation  of anti-Tac  through  the  experiment, 
whereas  anti-Tac  before  administration  was  >90%  bioactive 
(bindable). Five mice were used in each group. 
Labeled  Labeled  Unlabeled 
Expt. Form  protein  protein  protein, i.p. 
A3a  A*  13q-anti-Tac  125I-UPC 
(0.15 ~g;  1 pmol) 
A4a  A*B 2  131I-anti-Tac  12sI-UPC  Tac 
(0.15 I~g; 1 pmol)  (50 Izg; 2,000 pmol)* 
*Administered every 12-24 h 
Continuous infusion.  Animals were implanted subcutaneously 
with pumps secreting 131I Tac (B*),  then injected with i2si anti- 
Tac (A) or nonspecific IgG. Two or three mice were used in each 
group. 
Continuously infused  Bolus injected 
Expt.  Form  Labeled protein  Labeled protein 
B1  B*  131I-Tac  125I-UPC 
(2.6 I-~g; 80 pmol)  (200 p,g; 670 pmol) 
B2  AB*  13aI-Tac  125I-anti-Tac 
(2.6 Ixg; 80 pmol)  (200 p,g; 670 pmol) 
Labeled  Labeled  Unlabeled 
Expt. Form  protein  protein  protein 
A1  B*  13q-Tac  12sI-UPC 
(0.3 p,g; 10 pmol) 
A2  AB*  I31I-Tac  125I-UPC 
(0.3 p,g; 10 pmol) 
A3  A*  13q-anti-Tac  125I-UPC 
(0.15 Ixg; 1 pmol) 
A4  A*B  2  a3q-anti-Tac  125I-UPC 
(0.15 Izg; 1 pmol) 
anti-Tac 
(100 ~g; 670 pmol) 
Tac 
(100 l~g; 4,000 pmol) 
Derivation of Equations for Survival Kinetics and 
Anti- Tac [ Tac Interaction 
Bolus Intravenous Dosing.  The net clearance ofanti-Tac (A) is 
modeled as the  sum  of the  separate first order clearances of the 
three  States  of A  (1-3)  in  chemical  equilibrium  (Schema  2). 
Clearance of sTac (B) is similarly modeled by three States (2-4), 
in which two are shared with anti-Tac as complexes and the last 
is occupied by free sTac. (AB is similarly related to B as shown for 
AB  2,  as indicated by dashed lines.) The  interacting kinetics and 
equilibria  were  solved  numerically  (not  shown)  for  the  time- 
dependent concentrations of A, B, AB, and AB  2. 
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Continuous Infusion and Antigen  Steady State.  Where antigen is 
continuously produced, the formulation must include the pro- 
duction rate, q. In the absence of antibody: 
dB/dt  =  q-  k4B  (Eq.  10) 
Bss  =  q/k 4  (Eq. 11) 
In the presence of antibody, 
dBtot/dt  =  q -  kaB -  k2AB -  2  k3AB  2  (Eq,  12) 
This is solved numerically as above, from which Btot,ss is derived. 
Model Simplifications.  When  antigen binding does not affect 
antibody survival, the kinetic model may be reduced from four to 
two states: State 1: Tac bound and all anti-Tac forms, with a pro- 
longed  clearance;  State  2:  Tac  free,  with  a  rapid  clearance 
(Schema 3). This permits simplification of the rate equations 
dAtot/dt  =  -k 1 {A + AB + AB2}  =  (-klAtot)  (Eq.  13) 
dBtotldt =  -  {k4"  Y +  k 1 (1 -  ",/) } Bto  t =  -k'Bto  t  (Eq. 14) 
in which ~  =  B/Btot (the fraction of free Tac) and k' is a number- 
average rate constant that lies between that of antibody (kl) and 
free Tac (k4), biased by the fraction of bound versus free Tac; for 
large A, k' =  k  1. Eq. 14 retains the form of a first order differen- 
tial equation with log-linear plots for ~/constant over the experi- 
ment. The assumption of equal kinetic constants for Tac 03) and 
anti-Tac (A) in the santo  complex (AB or AB2) is a hypothesis 
tested in these studies. 
Schema 3. 
1  2 
anti-Tac and 
complexes  free Tac 
The simplified equations for antigen steady state are similarly: 
dBtot/dt  =  q -  k'Bto  t  (Eq.  15) 
Btot,~  =  q/k'  =  (qt'v2/ln2)  (Eq. 16) 
1This formulation should not  be  confused with classical compartmental 
analysis. The mouse is treated as a single physical compartment in which 
A and B move among the different States by a continuous equilibrium. 
The k values are the microscopic catabolic rate constants for each species. 
k4 is the same as km~ of Schema 1. The on and off rates for antigen with 
antibody [26] are rapid relative to the catabolic processes; their explicit 
representation does not materially alter conclusions, and are therefore 
omitted. The simulations are available  from the authors. 
For large A, k '=  k 1, and the new steady state is increased by k4/ 
k  1,  the  theoretical maximum.  Anticipating results in  text,  this 
maximum is k4/k2  Tac where catabolism of antigen-in-complex is 
faster than antibody-in-complex. 
Results 
Shedding of the IL2R  ct Subunit,  Tac 
There is no  independent secretory mRNA  for Tac that 
could undergo  independent regulation (27-29);  hence,  all 
sTac  is derived from proteolytic cleavage of TM-Tac  (9). 
We therefore wished to know the relation of Tac shedding 
to TM-Tac expression. 
Patients with adult T  cell leukemia (ATL) have elevated 
TM-Tac  on their malignant cells, but this expression may 
increase substantially during culture in vitro that is not seen 
with normal T  cells (30). For the patient of Fig. 1, TM-Tac 
expression increased progressively over the  4  d  period of 
the  assay.  Cell  number  was  stable  and  viability remained 
1>90%.  Therefore,  increased expression in  the  culture  re- 
flected increased expression per  cell, which  was  corrobo- 
rated on flow cytometry (not shown). The cumulative level 
ofsTac in the supernatant also increased during the period, 
such that by day 4 it exceeded TM-Tac on cells by a factor 
of 10  (Fig. 1  B),  although  TM-Tac  was  itself rapidly in- 
creasing over the same period. 
Shedding  of Tac  Is  First  Order  with  Respect  to  Membrane 
Tac.  We  consider two  general mechanisms  of shedding, 
saturable and nonsaturable.  If mechanisms  of shedding are 
saturable--as in a  typical Michaelis-Menton enzymic pro- 
cess--an  increase  in  TM-Tac  will yield a  less-than-pro- 
portionate  increase  in  sTac  shedding  as  saturation  is  ap- 
proached, yielding finally a zero order process with a fixed, 
"maximal" rate, although TM-Tac was increasing. If shed- 
ding mechanisms are not saturable--as in a spontaneous or 
autocatalytic process--the rate  of shedding should be first 
order and proportional to TM-Tac.  Stated alternately, the 
fractional shedding rate  in  a  first order process would be 
constant for all levels of TM-Tac, with an invariant tl/2;  in 
a  zero  order  process  (or  Michaelis-Menton  approaching 
saturation), fractional shedding would decrease with higher 
TM-Tac with a progressively increasing b/2. This situation, 
in which the same cells express different levels of TM-Tac 
over time, presents a special opportunity to distinguish be- 
tween these models of cellular shedding. 
sTac levels for each 24-h period were  fit to a  model in 
which sTac production was first order relative to TM-Tac 
expression (see Materials and Methods). TM-Tac increased 
almost 40-fold in the example of Fig. 1, from 5,000 mole- 
cules/cell to 180,000/cei1 over 4 d, yet the tl/2 was virtually 
constant for all levels of TM-Tac (Table 1; ATL1/1). Sim- 
ilarly, a survey of donor cell assays in Table 1, including the 
activated T  cells of a  normal donor,  shows  no  instance in 
which increasing TM-Tac  to high levels correlates with a 
prolonged q/2.  The relative constancy of tl/2 with different 
TM-Tac  expression  levels  in  individual  Tac-expressing 
malignancies and activated T  cells is compatible with a first 
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Figure  1.  TM-Tac  upregulation and high 
level sTac production by primary ATL cells  in 
culture. Cells were obtained from donor  1 
(Table 1)_  (A) Number of TM-Tac per cell 
and concentration  in U/ml ofsTac in the cul- 
ture medium. (/3) Total moles of Tac which 
are cell associated or soluble. (-D--) TM-Tac; 
(bars) sTac accumulation  between zero time 
and cell harvesting. 
order model. In addition, the same rapid tl/2 for Tac shed- 
ding is seen with a malignant T  cell line of activated phe- 
notype (HUT102) which constitutively expresses high lev- 
els of TM-Tac. A zero order or saturable model would have 
shown proportionately longer tl/2 with higher TM-Tac ex- 
pression, which was not observed. We may therefore ex- 
clude any simple zero order model to explain soluble Tac 
production. 
The determinations in Table 1 show a modal tl/2 of 2--6 h 
for Tac  shedding that  encompasses the  malignant T  cells 
from two  of six ATL patients, one malignant T  cell line, 
and normal activated T  cells. However, individual excep- 
tions were noted, with outliers at the high end where shed- 
ding was almost inapparent (tl/2 40--180 h), despite measur- 
able TM-Tac levels, and during late phases of normal T  cell 
activation (Table 1). 
When shed in vitro, Tac accumulates as a stable compo- 
nent in the  medium. In vivo, however,  Tac is  subject to 
the  normal catabolic activities of the  host,  which  occupy 
the remainder of this investigation. 
Metabolism of s Tac 
To  estimate the  in vivo fate  of sTac after it is  released 
from cells, we  investigated the  pharmacokinetic behavior 
of a recombinant human sTac protein in mice. Our initial 
studies examined the serum die-away profile to derive rate 
and volume constants via compartmental analysis. Tac was 
rapidly  cleared  in  a  two-phase  kinetic  pattern  (Fig.  2), 
Table 1.  Shedding  tl/2 Values Are Not Prolonged by High TM-Tac Levels 
Cell population studied 
ATL  1  / 1 
Shedding  Tac/cell  Activated 
Day  tl/2, h  ￿  10 -3  ATL1/2  ATL2  ATL3  ATL4  ATL5  ATL6  ProLL  Hut102  T cell 
0  (5)  (6)  (3)  (7)  (4)  (6)  (9)  (4)  (3) 
1  10.7  (30)  6.5  (33)  3.4  (8)  7.7  (9)  18.8  (14)  45.0  (16)  23.1  (4)  3.7  (90) 
2  6.0  (63)  3.2  (65)  1.3  (12)  8.0  (19)  11.3  (3)  13.9  (12)  190.2  (26)  109.7  (4)  4.4  (180)  3.2  (74) 
3  6.1  (141)  6.2  (63)  4.3  (16)  6.4  (22)  16.2  (7)  *  (7)  86.8  (23)  86.3  (3)  3.2  (59) 
4  5.6  (181)  3.9  (125)  3.7  (17)  14.4  (16)  10.3  (13)  *  (24)  (49) 
5  8.1  (3)  80.5  (5)  10.1  (24) 
6 
7 
8  59.9  (14) 
Primary malignant T cells or T cell line HUT102 were cultured and assayed at various times for TM-Tac and released sTac. tl/2 values in hours 
(bold) and TM-Tac ￿  10-3/cell (in parentheses) are represented, tl/2 values  were derived as in Materials and Methods. The two instances  for ATL1 
represent evaluations  before treatment and during a relapse 6 mo later. Too high culture cell number in ATL1/2 exhausted medium by day 3, slow- 
ing shedding and Tac upregulation, which both recovered with medium replenishment on day 3 (day 4 data). Activated T cell data were calculated 
from published data of  Jacques et al. [22] using rested T cell blasts that were stimulated at time zero. *Rate constant could not be calculated. 
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Figure 2.  Rapid loss ofsTac injected intravascularly.  Mice were injected 
with radiolabeled Tac with blood sampling for the protein bound fraction 
at indicated times ('"+'") and compared with the fractionated (protein- 
bound) whole body data (--￿  from a further experiment. The unfrac- 
tionated whole  body counts from both studies (not shown) indicated 
comparability of the experiments. (Bars) + 1 SE. 
whereas  a  typical slow  catabolism of coadministered IgG 
was observed (not shown,  but see Fig. 4  B). The terminal, 
[3-phase of the blood curve parallels the fractionated (pro- 
tein-associated) whole  body curve,  as  expected  (31).  The 
or-phases are not comparable because of key differences in 
the  formulations'  treatment  of the  distribution  constants: 
for blood, the rate of loss is accelerated by extravascular dis- 
tribution; for whole body, the rate of loss is delayed by ex- 
travascular  distribution.  The  derived  constants  from  the 
venous sampling of two experiments are listed in Table 2. 
The  elimination  rate  constant,  kmet,  of 0.49-0.63  h -1 
corresponds to a  catabolic ti/2  of 1.1-1.4  h.  Intercompart- 
mental transfer rates  (k~  e and  key; Schema  1)  are relatively 
directionally unbiased with tl/2  values of ~2  h,  suggesting 
passive distributive mechanisms. Two values for steady state 
volume  of distribution relative to  plasma volume  (~/V) 
are determinable: from the venous sampling curve fit, 2.4- 
2.6  (Table 2)  and  from  the  ratio  of area-under-the-curve 
values (not shown)  of the whole body and venous protein 
curves,  2.2  (Fig.  2).  Similar ratios  were  previously mea- 
sured for albumin and IgG (32). 
Thus, the metabolism of Tac presents a system in which 
the  catabolic rates are faster than  the  distribution rates,  as 
will be true of many soluble receptors and ligands that are 
small enough to pass the glomerular filter. This accordingly 
alters the  meaning  of or-  and  [3-phase kinetics relative to 
proteins with longer in vivo survivals. The or-phase kinetics 
of the whole body and, to a lesser degree, the blood curves 
are dominated by catabolism, and the J3-phase of the blood 
and whole body curves alike are dominated by distribution 
kinetics.  That  is,  the  J3-phase  represents  sTac  that  trans- 
ferred  to  tissue  during the  early phase  of the  experiment 
which is gradually returning to the vascular-catabolic com- 
partment  with  a  consequent  delay in  catabolism.  It is ac- 
cordingly  noted  that  neither  macroscopic  constant  ade- 
quately  represents  the  true  microscopic  catabolic  rate 
constant.  However,  this  catabolic  constant  can  be  deter- 
mined as indicated in Table 2. 
Extravascular to Intravascular Transport of Tac.  Tac-express- 
ing malignant cells or activated T  cells are located mainly in 
the spleen, lymph nodes,  skin,  and  other tissues. Elemen- 
tary pharmacokinetic  principles dictate  that  catabolism of 
Tac released into these tissues will be delayed by the time 
required for Tac  to pass from tissue to blood if that tissue 
does  not  contribute  to  the  short-term  catabolism of Tac. 
Venous  sampling suggested  transport  to  blood with  a  kcv 
"~0.3-0.4 h -1 and a slightly faster reverse rate (Table 2). To 
Table 2.  Kinetic Constants Demonstrating Pattern of Normal  Tac Distribution and Catabolism 
Kinetic constants  Derived  tl/2 values 
Expt. 1  Expt. 2  Expt. 1  Expt. 2 
h -I  h 
ot  (Macroscopic rate constant)  1.12 (0.17)  1.10 (0.06)  0.62  0.63 
[3  (Macroscopic rate constant)  0.14 (0.04)  0.14 (0.01)  4.95  4.95 
k ....  (Metabolic rate constant)  0.63 (0.05)  0.49 (0.02)  1.10  1.41 
k~e  (Vascular to extravascular rate)  0.38 (0.10)  0.45 (0.03)  1.82  1.54 
key  (Extravascular to vascular rate)  0.26 (0.09)  0.32 (0.03)  2.67  2.17 
VJV  (Normalized distributionvolume)  2.6  (0.48)  2.4  (0.10) 
Kinetic constants were derived by two-compartment modeling (Schema 1) as in Materials and Methods. Expt. l is represented in Fig. 2; expt. 2 in- 
volving nine mice is not shown. Fitting errors are in parentheses, ct and ~3 are the macroscopic rate constants. The microscopic constants are kmet, the 
overall metabolic rate constant, and/eve and key, the rate constants for transfer from blood to tissue and from tissue to blood. Vss/V is the distribution 
volume at steady state as a multiple of the plasma volume (the initial volume of distribution). 
1592  Metabolism of Tac mimic this in vivo situation more directly, we investigated 
the  peritoneum  as  an  extravascular  site  for  Tac  adminis- 
tration. 
Fig. 3 shows a comparison of blood and whole body ki- 
netics  of animals  administered  Tac  by i.v.  or i.p.  routes. 
The blood kinetics after i.v. injection show an c~-phase tl/2 
of 0.6  h,  comparable with  that  of Fig.  2,  representing  the 
sum of catabolism and distribution.  In contrast, the i.p.  in- 
jection  shows  a  delayed transfer  of radioactivity from the 
peritoneum to the blood over a period of 2 h and then dis- 
plays loss kinetics with a tl/2  of 4  h  that is paralleled in the 
whole body curves  (Fig.  3  B).  The 4-h tl/2  of intraperito- 
neaUy injected  material  is  comparable  to the  5-h terminal 
tl/2  of the i.v.  data of Fig. 2, which was interpreted  as the 
delayed return to blood of sTac that transferred extravascu- 
lady. The control IgG transports from peritoneum to blood 
and then remains stable over the remainder  of the  experi- 
ment. A  further comparison ofi.p,  and s.c. administrations 
of Tac  suggested  comparable  transfer  rates  to blood from 
either  of these  two  extravascular  sites  (not  shown).  We 
conclude that  Tac  shed into  tissues  will be  transported  to 
the vascular space and catabolized with a combined t~/2 for 
the transport and catabolic processes of about 4-5 h, adding 
3-4 h of net delay to the catabolic tl/2 of Tac in blood. 
Renal  Catabolism  of Tac.  Small  proteins  such  as  Bence 
Jones proteins (Ig L chain monomer [22 kD] and dimer [44 
kD])  are cleared primarily by renal mechanisms with a se- 
rum  tl/2  of ~1  h  in humans  and in mice,  which typically 
parallel  humans in the handling of proteins by the kidney 
(23, 24, 31, 33). Our studies demonstrating rapid clearance 
of Tac  led  to  our  hypothesis  of renal  catabolism  for this 
~30kD  (33a) glycoprotein as well. 
The role of the kidney in catabolism of Tac was assessed 
by nephrectomy in mice.  The  ratio  of catabolic  rates be- 
tween  control  and  nephrectomized  animals  indicates  the 
fraction  of catabolism  attributable  to  kidney.  Ureter  liga- 
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tion inhibits filtration by 11-67% over the first 8 h  (34, 35) 
and  provides  a  setting  of moderately  reduced  GFR.  Be- 
cause whole body sampling represents  the sum of vascular 
and extravascular compartments, the distribution of protein 
to tissue delays the loss kinetics in contrast to venous sam- 
pling in which distribution  accelerates loss kinetics.  In this 
setting, the catabolic rate constant is obtained from the ini- 
tial  time  kinetics  when  the  system approximates  a  single, 
vascular compartment. 
As  for  the  venous  sampling  studies,  131I-Tac  was  co- 
injected with 125I-irrelevant IgG as a large protein not nor- 
mally catabolized in the kidney (Fig. 4).  The catabolic rate 
constants  (kmet) and time  to catabolism of 50%  of injected 
Tac were 0.72  h -1  for control mice  (tl/2  1.0 h),  0.28  h -1 
for ureter-ligated  mice  (tl/2  2.4  h),  and  0.07  h -1  for ne- 
phrectomized mice (tl/2  10 h)  (Table  3).  These rates indi- 
cate that 90% of catabolism is renal with the remaining 10% 
due  to other tissues.  In contrast,  the concentration of IgG 
remained  high  over the  study period  for normal,  ureter- 
ligated and nephrectomized mice in accord with prior re- 
sults  (23).  The catabolic  rate  constant,  kmet, represents  the 
sum of renal (kr) and nonrenal (k,r)  terms (Eq. 5). Assigning 
0.07 h -1 to k~ from the nephrectomy data, we infer a rate 
constant  of 0.72-0.07  =  0.65  h -1  for kr in normal  mice. 
For the ureter-ligated animals,  kr is 0.28-0.07  =  0.21  h -1, 
indicating  a  68%  reduction  in  GFR,  which  is  compatible 
with expected GFR loss (34, 35). From Eq. 9, we derive a 
renal filtration ratio of0.11 for Tac relative to creatinine. 
All whole body sTac curves in Fig. 4 A  show progressive 
prolongation of survival with time. For the normal animals, 
this may be explained (above) by the portion ofsTac pene- 
trating  extravascular  tissues  during  the  first  4  h  that  then 
diffused back into the blood to gain access to the renal cat- 
abolic compartment, as shown previously for L chain dimers 
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Figure  3.  Slower loss of sTac injected intraperitoneally. (A) Blood ki- 
netics. A mixture of 131I-Tac (closed symbols) and 12sI-UPC (open symbols) 
was injected intraperitoneaUy in two mice (&, A, mouse 1; II, IS], mouse 
2). Superimposed  in this graph are the serum loss kinetics from other mice 
injected with Tac intravenously (-..+...). (B) Whole body unfractionated 
loss kinetics of intraperitoneally injected I3q-Tac. Symbols as in A. The 
stair-step effect of whole body loss reflects voiding intervals of the mice; 
this imposes a lag on the kinetics but does not affect the slope (k). 
B 
HRS 
Figure 4.  The kidney is the principal site of  Tac metabolism. Mice were 
control (unoperated) or operated with nephrectomy or ureter ligation and 
administered 13q-Tac plus 125I-UPC, a nonspecific mouse monoclonal 
IgG. Animals were killed at indicated times and assayed  for protein-bound 
radioactivity in whole body homogenates as in Materials and Methods. 
Two to five mice were used for each time point. (Bars) +1 SE. (A) 131I- 
Tac, (B) 125I-UPC. (HI) Nephrectomy; (A) ureter ligated; (-  ￿  --) nor- 
mal; and ('"￿  linearized a-phase of "normals" curve. The linearized 
a-phase was derived from the full curve of  control whole body data (trun- 
cated for graphing purposes) by curve stripping; the 13 phase tl/2 was 4 h. 
1593  Junghans  and Waldmann Table 3.  Kinetic  Constants Demonstrating Role of Kidney in Tac Metabolism 
Percent metabolism  Percent metabolism 
kme  t  Protein  tl/2  due to catabolism  due to proteinuria 
h -1  h 
Control  0.72 (0.06)  1.0  97-99%  1-3% 
Ureter ligated  0.28 (0.03)  2.4  N/A  N/A 
Nephrectomy  0.07 (0.01)  10.2  N/A  N/A 
The data of Fig. 4 were analyzed by curve stripping to define the ~x-phase of  the control animals, and derived graphically for the two operated sets of 
animals. In this experimental design, the derived macroscopic ~x-phase rate constant equals the microscopic metabolic rate constant (kmet) (Materials 
and Methods). N/A, not applicable. 
(23). These considerations should apply equally to the ure- 
ter-ligated animals that retain 30% of GFR, but these inter- 
compartmental rates are less important in the [3 phase when 
catabolism is slower. The plateaus after 8 h in ureter-ligated 
and  nephrectomized  mice  are  probably  due  to  uremia- 
induced suppression of catabolism in these animals, as pre- 
viously shown (23). 
Renal Excretion of Tac.  The  excretion  products  after 
125I-Tac  administration  were  examined  to  quantitate  the 
degree  of proteinuria.  Inasmuch  as  the  tissue-catabolized 
125I-Tac will release iodide and iodotyrosine to the kidneys, 
urinary collection represents  the sum of all catabolic prod- 
ucts  rather  than just  those  generated  by the  kidney.  The 
spot urine of three normal mice 6 h  after injection and the 
cumulative  48-h  collections  on  a  further  three  animals 
showed comparable fractions of protein-associated radioac- 
tivity  (0.7-2.3  and  1.2-3.3%,  respectively).  The remaining 
97-99% was degraded to low molecular weight radioiodine 
products (Fig. 5), interpreted principally as free iodide (36). 
Thus, of the sTac entering the blood,  10% is catabolized at 
external sites  and the remaining 90% is filtered through the 
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Figure 5.  Minor loss of  Tac by proteinuria. The urinary products of  Tac 
metabolism were examined by Sephadex G25 chromatography  of  the cu- 
mulative 48-h urine output  of two mice after t2SI-Tac administration 
(-- ￿9  --, -- ￿9  --). As control, the profile of a 12SI-sTac preparation 
with 5% free iodide is shown ("" ￿ 
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glomerulus.  Of this 90% renal metabolism,  1-3% is due to 
proteinuria; the remaining portion (87-89%) of Tac passing 
the glomemlar filter is catabolized in the renal tubules (24, 33). 
Fig. 6 summarizes the data on the generation and normal 
catabolism of soluble Tac. 
Antibody Inhibits Tac Catabolism 
During  antibody therapies,  the binding to soluble  anti- 
gen has the potential to disturb the receptor's normal catab- 
olism. To define the impact of this interaction, two experi- 
mental  approaches  were  employed:  (a)  an  i.v.  bolus 
injection  model  to  derive  catabolic  constants,  and  (b)  a 
continuous production model to measure changes in steady 
state soluble receptor levels. 
Bolus Injection: Anti-Tac Binding Prolongs In  Vivo Survival 
of Tac.  The  survivals  of radiolabeled  Tac  (B*),  radiola- 
beled  anti-Tac  (A*),  and  their  complexes were examined. 
Inspection of Schema 4 reveals that only four species can be 
studied directly: the free forms, B* and A*, and their satu- 
rated complexes, AB* and A'B2; the crossed forms can only 
be created in the presence of additional labeled species. 
Schema 4. 
B* 
Tac 
A* 
anti-Tac 
COMPLEXES 
anti-Tac I  Tac  anti-Tac I  Tac2 
uncomptexed  AB  AB  2 
B* 
A* 
\  /  "\  // 
AB*  AB*  2 
\\\  / 
A*B  A*B  2 
Kinetics analysis of the survival of Tac alone (B*) showed 
a [3 tl/2 of"-'5 h and a catabolic tl/2 ofl.4 h  (Fig. 7 and Ta- 
ble 4), reflecting the dominance ofintercompartmental rate 
constants previously noted (Fig. 2 and Table 2).  The addi- G 
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Figure 6.  Model of Tac shedding and 
normal catabolism. (A) Expression. TM- 
Tac  is  upregulated  via  nuclear  factor- 
KB-like element interactions in response 
to  activation  or  viral-induced  factors. 
(/3)  Shedding.  Shedding  occurs  with  a 
modal tl/2  of 2-6 h (k ~  0.1-0.3 h -1) af- 
ter activation or in malignancy. Diver- 
gence from this number may be due to 
dysregulation of coexpressed membrane 
proteases  and/or  glycosylation  differ- 
ences. (C) Distribution. sTac released in 
or returning to tissues is governed by bi- 
directional  rate  constants  of "-~0.3-0.4 
h -t with a net increase in survival t~/2 of 
+3--4  h  over  a  single  (vascular)  com- 
partment.  (D)  Filtration.  Tac  reaching 
the  vascular  compartment,  or  released 
from  circulating  cells,  is  90%  filtered 
through the glorneruli at '-'0.7 rnl/h in 
mice (11% of GFI~)  and, by extension, 
~800 ml/h in humans. (E)  Catabolism. 
10%  of catabolism  occurs  in  nonrenal 
tissues with a tl/2  of 10 h  (knr 0.07 h-I), 
and 90% is mediated by the kidney (k) 
0.65 h-~), yielding a net catabolic tl/2  of 
,'--'1-1.4  h  from  blood.  After filtration, 
97-99%  of sTac  undergoes tubular re- 
sorption and degradation to amino acids 
with reutilization. (Fr3 Excretion. A small 
(1-3%)  fraction  of filtered  sTac  is  ex- 
creted intact as proteinuria. 
tion  of anti-Tac  antibody increased  Tac*  (AB*)  survival, 
with a 13 tv2  of 38 h for Tac in the presence of excess anti- 
Tac and a catabolic tl/2  of 24 h, more than  15-fold above 
the  1.4-h  catabolic  t~/2 measured for unbound  Tac  (B*). 
Anti-Tac antibody (A*) showed a 13 tt/2 of  82 h, with a cor- 
responding catabolic tl/2  of 43 h, typical of mAbs in mice. 
The tl/2  for radiolabeled bound Tac (AB*) is significantly 
different from radiolabeled anti-Tac (A*) (p <0.001). 
Because of concerns over the the design of this experi- 
ment to maintain excess B over A* beyond 60 h  (Expt. A4, 
Materials  and  Methods),  a  more  rigorous  test  was  per- 
formed, in which antigen excess was maintained via recur- 
rent i.p. Tac (I3) dosing (Fig. 8). The new rate ofanti-Tac* 
decline after Tac dosing was not different from that in mice 
with no antigen administration  (p  =  NS  for all compari- 
sons)  (Table 5). We conclude that saturation binding with 
Tac antigen does not alter antibody survival, that is, A*B  2 
survives equal to A*. 
An unexpected feature of the data of Fig. 8 was the posi- 
tive increment of ~3q-anti-Tac* radioactivity in the blood 
after the first Tac dose, which was not seen in the control 
group. This was observed in each of the five mice in this 
test,  and it was  not  observed in  the  nonspecific 125I-IgG 
control antibody that was coadministered in the same mice 
(not  shown).  Different  physiologic  phenomena  may  be 
posited for this observation, but this was not a focus of our 
study and we did not investigate it further. 
These survival data  (Tables 4  and  5)  present us with a 
further surprising result.  Paradoxically, anti-Tac  (A*) and 
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bisaturated anti-Tac complex (A'Be) were equal, suggesting 
no effect of Tac binding on antibody survival, yet the clear- 
ance  of the  monosaturated  anti-Tac  complex with  Tac- 
labeled (AB*) was significantly faster than either, although 
it is  intermediate  structurally between  them  (Schema 4). 
Accordingly, the equivalence of the clearance rates of A*, 
A*B (presumed, supra)  and A*B  2 versus the apparent faster 
clearance of AB* suggests  a  compromise between  (a)  the 
accelerated clearance of dissociated Tac, and  (b)  the pro- 
longed survival of Tac complexed with antibody. To ex- 
amine this hypothesis, we modeled the setting in which kl 
=  k 2  =  k 3 and the rate constants  k 2 and  k 3 apply to both 
members  of each  complex  (Schema  2).  We  then  tested 
whether the predicted fraction of free Tac (t3") could ex- 
plain the accelerated clearance of Tac* in the AB* complex 
versus anti-Tac (A) in the same complex. The equation for 
this setting is (Schema 3): 
aBtotldt  =  -  {k4~  /  +  k~ (1 -  "t) } Btot =  k'Btot  (Eq.  14) 
At  the  concentrations of anti-Tac present,  ~  <  0.001 
(the fraction of free Tac, B/BtoO,  and  the net survival of 
Tac  (k')  should have been indistinguishable  from that  of 
the antibody (kl). Yet the survival of Tac-in-complex (Ta- 
ble 4) is only 55% of that predicted. Analysis  of the termi- 
nal decay phase and steady state levels of Fig.  9 below and 
other  tests  not  shown  likewise  demonstrate  significantly 
low fractions (35-45%)  of predicted survival and concen- 
trations ofsTac by this model. Therefore, we conclude that 
this hypothesis--that the fraction of Tac that exists dissoci- 180 
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Figure  7.  Prolongation of Tac survival in vivo by anti-Tac binding. 
Samples were prepared and administered intravenously to four groups of 
animals as in  Materials and Methods. (A)  Blood die-away curves for 
~3q-Tac* alone, B* (--&--); Tac* plus excess unlabeled anti-Tac, AB* 
(--A--); and 13~l-anti-Tac*, A* (~);  anti-Tac* plus excess unlabeled 
Tac, A*B  2 (--[]--).  (B) Blood die-away curves for 125I irrelevant IgG 
(UPC) coadministered in the experiments of A with corresponding  sym- 
bols; that is, t2sI-UPC in the experiment with B* (--A--); in the experi- 
ment with AB* (--Z~--); in the experiment with A* (--I--); and in the 
experiment with  A*B  2 (--[]--).  SE  not shown, equals 0-3%  for  all 
points. 
ated in the circulation explains the more rapid net clearance 
rate--is  incompatible  with  the  data  and must be rejected. 
The  alternative  is  that  catabolism  of Tac-in-complex  is 
genuinely faster than antibody-in-complex. This is consid- 
ered in the Discussion. 
Micropump Infusion: Anti-Tac Increases Steady State Concen- 
trations of Tac in Blood.  During  T  cell  activation and  ma- 
lignancy in  vivo, sTac  is  continuously produced  by Tac- 
expressing  cells,  which  are  concentrated  in  extravascular 
tissues.  To  model this  biologically relevant  condition,  we 
observed Tac levels in mice with implanted microosmotic 
pumps.  Similar kinetics  and steady state blood levels from 
s.c. or i.p. implantation  (not shown)  confirm that the pro- 
duction of Tac in alternative  extravascular sites will not be 
greatly site-sensitive in evaluating metabolism. 
To mimic the therapeutic setting, we then examined the 
impact  of specific  antibody.  20  h  after  pump  placement, 
mice were injected intraperitoneally with a large excess of 
t2SI-anti-Tac  (A)  (Fig.  9).  In contrast  to  the  control  Tac 
(B*)  infusion,  which  was  already  stable  at  the  20-h  time 
point,  the  concentration  of Tac  with  anti-Tac  injection 
(AB*) was just approaching plateau at the time of pump ex- 
piration after day 7. The blood-soluble Tac level increased 
11-fold with anti-Tac antibody during the experiment,  and 
was projected by graphical methods to plateau  finally at a 
13-fold  increase.  At  no  time,  however,  did  Tac  reach  a 
concentration  that could saturate  antibody,  which was al- 
ways at least  100-fold in molar excess. After pump expira- 
tion, AB* complex declined with a terminal  ~  tl/2 of 41  h 
that  compares  with  the  38-h  [3  h/2  after  bolus  injection 
(Table 4). 
These  studies  indicate  that  the  blood  concentration  of 
Tac  was  increased  more  than  10-fold by the  presence  of 
anti-Tac. This change in concentration occurred in the ab- 
sence of any alteration in the rate of Tac delivery into the 
system ("production") and was therefore due solely to sup- 
pression of catabolism and prolongation of Tac survival. 
Discussion 
A  wide array of cell surface proteins are present in solu- 
ble form in blood that have been assessed for clinical  and 
biological  significance.  Some,  such  as  B  cell  IgG,  derive 
from alternately  spliced mRNAs that yield the membrane 
and secreted forms.  For all  others,  the TM protein is shed 
to generate the soluble form. Phospholipases may be respon- 
sible in some instances, but most are thought to be cleaved 
by membrane-associated  proteases  (6,  37-40),  including at 
least  one phosphoinositol-linked  protein  (41).  Despite  the 
importance  of this  feature  (shedding)  and  the  number  of 
relevant  molecules,  a  recent  review  concluded  that  "no 
convincing  candidate  for  a  [shedding  protease]  has  been 
unequivocally identified  and isolated"  (6).  To our knowl- 
edge, this statement remains true.  It is notable that the only 
Table 4.  Anti-Tac Prolongs Tac Survival 
Difference 
Fore1  Description  ~ t~/2  Catabolic rate constant  Catabolic tl/2  versus A* 
h  h -1  h 
B*  Tac*  4.8 (0.4)  0.485 (0.016)  (k4)  1.43 (0.05)  p <0.001 
AB*  Tac* +  excess anti-Tac  38 (1)  0.0294 (0.0008)  (kz)  23.6 (0.6)  p <0.001 
A*  Anti-Tac*  82 (2)  0.0160 (0.0002)  (k  0  43.1  (0.6) 
Constants (and fitting errors) were derived from two-compartment analysis of the data of Fig. 7A. A*B  2, radiolabled anti-Tac saturated with excess 
cold Tac, is not represented in this table but is separately compared with A* in Table 5. The kinetic constants (k4, k2, k0, are defined in Schema 2. 
The catabolic constants were compared with anti-Tac (A*) by Student's t test. 
1596  Metabolism of Tac Table 5.  sTac Does Not Alter Anti- Tac Survival 
t1/2  tl/2  tl/2 
Form  Description  full range  before injection  after injection 
(a) 
A*  Anti-Tac*  5.4 (0.3)  4.5 (1.0)  6.2 (0.8) 
A'B2  Anti-Tac* +  excess sTac  5.5 (0.4)  5.1 (0.4)  5.8 (0.3) 
p value  NS  NS  NS 
Constants were derived from regression analysis of the data of Fig. 8. The macroscopic 13 tl/2 values (and fitting errors) are expressed in units of days. 
The full range applies to the approximately linear phase between 1.5 and 6.5 d on the control anti-Tac* (A*) injection. Because of the positive dis- 
placement of the A*B  2 curve, a full range 13 was derived as a weighted average of the before injection and after injection averages. The time points 
before injection are 1.5-3.5 d, and after injection are 3.5-6.5 d. There are no significant differences between the control and experimental slopes by 
Student's t test. 
example to date of a defined shedding mechanism is that of 
Fc~R-II, which is autoproteolytic (42). 
Like other proteins,  the mechanism  of Tac  shedding is 
unknown.  It  proceeds  in  the  absence  of serum,  is  not 
blocked by several serine protease inhibitors, zinc chelators, 
or  cysteine-reactive  agents,  and  is  uninfluenced  by  the 
presence or absence of IL2 (9,  and R.P. Junghans,  unpub- 
lished  results).  The  site  of Tac  cleavage  was  defined  by 
R.obb and Kutny (9)  as the Cyst92-Leu  193 bond, for which 
no specific protease has to our knowledge been described. 
Mullberg et al.  (39)  made the cogent observation that the 
position from the membrane may be more important than 
the  sequence  for  IL6  receptor  shedding,  but  the  strong 
conservation between mouse and human  of a  discrete do- 
main surrounding the Tac  cleavage site (12/13  =  93%)  is 
reminiscent  of  the  conservation  of  cleavage  motiE  for 
membrane protein processing in paramyxo- and lentiviruses 
tional rate is not uniform across all settings. Accordingly, all 
models are constrained to appear first order over the range 
of TM-Tac here, yet must incorporate a potential for inter- 
individual variation in absolute fractional rates of shedding. 
Both true first order (autocatalytic) and Michaelis-Menton 
(enzymic)  mechanisms  can  be  accommodated,  but  with 
significant restrictions to each. 
Differences in the shedding rate constant in a first order 
model may be accommodated by modification of the pro- 
tein itself, for which role glycosylation is postulated to pro- 
tect against degradative proteases (44) and is particularly apt 
as a candidate mechanism. Removal of an O-glycosylation 
site in transferrin receptor, for example, markedly acceler- 
ates release of the soluble form  (45).  Tac has O-glycosyla- 
tion  sites in  proximity to  the  Cys192-Leu  193  cleavage  site 
(46), and glycosylation patterns for Tac in normal and ma- 
(43) and suggests the sequence is crucial to Tac shedding. 
10- 
Our  two  key  experimental  observations  pertinent  to  ~o  ~  i\ 
mechanism are: (a) shedding is nonsaturable over a two-log  ~  s  i "  '~  ,=  ~  f  - 
range  of substrate  TM-Tac  expression;  and  (b)  the  frac-  Pa 
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Figure 8.  Undisturbed anti-Tac survival in vivo with soluble Tac bind- 
ing. The experiment was performed as in Materials and Methods, with 
the first dose of 50 p~g ofTac i.p. at 75 h (arrow)  in the experimental series 
with repeat dosing every 12-24 h until the end of the experiment, anti- 
Tac*, A* (--I---); anti-Tac* plus excess unlabeled Tac, A*B  2 (--IS]---). 
(Bars) ---+1 SE. 
TIMES,  DAYS 
Figure 9.  Increased Tac levels with anti-Tac administration in model of 
constant m  vivo antigen production.  Pumps (7 d)  containing 13q-Tac 
were inserted subcutaneously (Materials and Methods). A large excess of 
125I-anti-Tac or 1251 irrelevant IgG (UPC) was given by i.p. bolus at 20 h 
(arrow) as Tac levels approached steady state. Results from two or three 
mice are pooled in each experiment for graphing. 13q-Tac, B* (--&--); 
13q-Tac plus excess anti-Tac, AB* (--A--). ~25I-anti-Tac,  A (...-), to es- 
timate the anti-Tac excess: the lowest anti-Tac (A) levels were 80 Ixg/ml 
plasma or "~500 nM; the highest soluble Tac levels in the AB* mice were 
5nM. 
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proteins  (28, 47). Whether this pattern also changes during 
T  cell  activation  and  downregulation  of Tac  is,  to  our 
knowledge, unknown. 
On  the  other  hand,  this  variation  in  shedding  rates  is 
what most suggests a separately regulated protease. If such a 
"shedding  protease"  is present,  it appears to be membrane 
bound  because  (a)  shedding  proceeds  in  serum-free  me- 
dium, and (b) early and late rates of shedding are constant-- 
medium accumulation  of a secreted protease would be ex- 
pected to progressively accelerate shedding.  A  recently de- 
scribed matrix metalloenzyme is such a membrane protease 
(48). The unusual character of the Tac cleavage site and the 
resistance of Tac shedding to several protease inhibitors  ar- 
gue against a range of nonspecific proteases, but the activity 
must be widespread, including lymphoid and nonlymphoid 
cell  lines  of human  and  nonhuman  origin,  since  all  such 
cells shed eflficiently when transfected with human TM-Tac 
(29;  and R.P. Junghans,  unpublished  results).  "Widespread 
expression" is expected for an autocatalytic model. Finally, 
it can be shown that the first order kinetic pattern imposes 
a  high  Km on such  a protease,  or it implies compensating 
substrate  modification  by  altered  glycosylation  at  high 
TM-Tac  levels  and/or  coordinate  regulation  of the  pro- 
tease.  Protein  kinase  C  has been implicated as an activator 
for a putative shedding protease in one case (37). 
Whichever  mechanism  underlies  the  shedding  process, 
shedding could have as its normal role to increase receptor 
release  with  activation  with  subsequent  return  to  baseline 
activity  once  the  activation  stimulus  is  removed.  This 
would  promote  rapid  downregulation  of Tac  expression 
and  IL-2 responsiveness with withdrawal  of the  activating 
stimulus,  at  a  time  when  maintaining  the  activated  state 
would be counterproductive  to the host. 
Once Tac is shed as a soluble protein,  it is subject to the 
catabolic activities of the host. We studied exogenously ad- 
ministered human sTac in a mouse model, which typically 
parallels  humans  in  metabolic  handling  of proteins,  sTac 
was rapidly cleared after i.v. injection with a nominal tl/2 of 
1  h  that  increased  to  10  h  in  nephrectomized  mice.  We 
conclude that Tac is 90% catabolized by the kidney, with a 
filtration fraction of 0.11,  and the remaining  10% of catab- 
olism is accounted for by nonrenal tissues (Fig. 6). After fil- 
tration,  all  protein  is  either  absorbed  in  the  tubules  and 
catabolized to amino acids with reutilization,  or excreted as 
proteinuria  (24), documented  as  1-3% in our experiments. 
Extrapolating to humans,  with a normal mean serum sTac 
of 175  U/ml,  a  creatinine  clearance  of 180  liters per  day, 
and an 11% of GFR filtration ratio for Tac from our result 
in  mice,  we  estimate  a  daily filtration  of 3.5  ￿  106  U  of 
Tac and production (and total metabolism) of 4  ￿  106 U  of 
Tac (12 Ixg). Urinary clearance (proteinuria)  ofsTac in hu- 
mans  was measured  at  1.1  ￿  10 s  U  per  24  h  (13),  from 
which  we  estimate  a  mean  normal proteinuric  rate  of 3% 
relative to total catabolism, which corresponds closely with 
our result in mice (1-3%)  and with L  chain proteinuria  in 
humans  (~1%)  (33).  In  all  respects,  these  data  with  sTac 
parallel the metabolic fate of Bence-Jones proteins and iso- 
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lated  L  chain  in  mice  and  in  humans  (23,  24,  33).  This 
clearance pattern is likely to be shared by all shed molecules 
of a size small enough to pass the renal filter (< ~50 kD). 
With  this picture  of normal Tac catabolism, we consid- 
ered the  potential  of two  settings  to  perturb  this  balance. 
One  is the  pathologic  changes  associated with kidney  dis- 
ease; the  other is the  iatrogenic  condition  imposed during 
therapies  with  antibodies  or  other  antireceptor  molecules. 
The 68% reduction  of renal catabolism of Tac with ureter 
ligation  (Fig.  4)  is compatible with the impact on GFR in 
the  hours  after ligation  (34,  35).  Reduced  catabolism  ac- 
companying reduced  GFR is predicted  to increase plasma 
levels  of  endogenously  generated  sTac,  as  modeled  in 
Fig.  10. Since the major part of catabolism is kidney depen- 
dent,  sTac increases roughly with creatinine  for low creat- 
inines until nonrenal  catabolism becomes a significant por- 
tion  of  the  total.  Ultimately,  in  anephric  patients  on 
hemodialysis, creatinine is filtered but molecules the size of 
Tac  are  not,  and  all  catabolism  is  nonrenal,  predicting 
plasma levels  11  times  normal  without  any  change  in  the 
rate of Tac synthesis and release. 
In contrast  to filtration,  tubular  dysfunction  has no  im- 
pact on blood levels but only increases the proteinuric frac- 
tion  concomitant  with  the  decreased  tubular  protein  re- 
sorption.  Urinary  Tac  has been  used  as  a  measure  of Tac 
expression in malignancy and in allo- and autoimmune set- 
tings  (10,  13).  However,  urinary  Tac will  be dramatically 
increased in rejection and other renal diseases with a tubu- 
lar component,  for which  there  is no valid normalization. 
Given the  additional  hazards  of urinary  Tac interpretation 
relative to serum, with six-fold interindividual  variation in 
proteinuric  fractions among human  "norriaals"  (13)  (three- 
fold in  our mice),  there  is probably no justifiable  role  for 
urinary Tac measurements in any setting. 
We then examined the effect of antibody binding on the 
catabolism  of Tac,  which  shares  many features  with  renal 
failure without the systemic physiologic consequences.  The 
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Figure  10.  Decreased GFtk  predicts increased plasma Tac  with  no 
change in sTac production. Relative increase in creatinine with normal 
defined as 1, and fraction of normal GFR represented as the inverse of the 
relative creatinine. NB: This relation is not applicable in hemodialysis, in 
which creatinine is filtered and Tac is not. combination  of molecules with  different native  catabolic 
rates  will  have  different  outcomes,  depending  upon  the 
mechanisms of clearance. For example, when antidigitoxin 
Fab  antibodies  were  administered to  neutralize digitoxin, 
the abbreviated survival of the Fab fragment was imposed 
on the slow tl/2  of free drug, leading to a marked accelera- 
tion in drug clearance (49). When complete IgG antibodies 
are themselves the target of antibody-mediated immune re- 
actions, their clearance is usually also greatly accelerated by 
specific host mechanisms (16). Rapidly catabolized compo- 
nents may alternately have their catabolism delayed by anti- 
body reaction, as first shown for anti-insulin antibodies by 
Berson and Yalow (50).  Similarly, we show that a biologi- 
cally and clinically important target antigen in soluble form 
can have its survival markedly prolonged by the interaction 
with antibody. In contrast, we noted that antibody survival 
was unaffected by antigen binding. 
When antibody elicits antiglobulin responses in vivo, ev- 
ery epitope is repeated twice in IgG (10 times in IgM), and 
the polyclonality of the response ensures that many epitopes 
will be targeted, yielding large aggregates that present mul- 
tivalent Fc to the FcR of the monocyte-macrophage sys- 
tem, and leading to rapid systemic clearance. That anti-Tac 
survival is unaffected by antigen binding is probably due to 
the fact that Tac is monomeric and presents a single bind- 
ing  epitope  to  antibody,  which  is  itself  monospecific, 
thereby  avoiding  formation  of  higher  aggregates.  This 
should  also  be  generally  true  for  other  mAbs  targeting 
monomeric soluble proteins.  Furthermore, the size  of the 
antibody was not greatly increased by reaction with anti- 
gen.  The fully saturated  anti-TacITac  2 complex (AB2) is 
~220 versus 160 kD for antibody alone, far below that of 
other serum proteins such as IgM and complement compo- 
nent C1  (each 900--1,000 kD). The tl/2  of lgM in humans 
is 5 d (31), and greater size alone is insufficient to accelerate 
clearance. 
In  contrast,  Tac  survival  increased  more  than  15-fold 
with antibody binding, from a nominal 1.4-h catabolic tl/2 
to 24 h for i.v. injected material. The failure of Tac to pass 
the glomerular filter when bound to antibody is presumed 
to be the  cause  of prolonged Tac survival in the  present 
studies, yielding the equivalent of total renal failure for Tac 
metabolism.  Yet  the  survival  of Tac-in-complex  is  also 
much longer than measured for nonrenal catabolism (cata- 
bolic tl/2 ~" 10 h), and antibody evidently protects Tac from 
this catabolism as well. 
To mimic the in vivo setting of human therapies, we ap- 
plied  a  continuous  production model  in  mice  using  im- 
plantable microosmotic pumps.  As a concomitant of pro- 
longed survival, this model showed increased steady state 
levels of Tac in the presence of antibody. The steady state 
concentration (B~s) is a simple function of the rate of pro- 
duction times the catabolic tl/2 (not the [3 tl/2; See Materials 
and Methods): 
Bss  =  qlk  =  q  tl1211n2  (Eq. 10) 
If the  tl/2  is changed by antibody, then the new steady 
state for the  sum  of all B  forms, B'tot  .... is  related to  the 
former steady state by the ratio of the net tl/2 values: 
B  !  ~  Y  tot,ss/Btot,ss  t 1/2/tl/2  (Eq. 11) 
We measured the tl/2 for Tac complexed with anti-Tac as 
23.6 h versus a value of 1.4 h for Tac alone (Table 4), pre- 
dicting  a  final  steady  state  increase  of 16.5-fold.  This  is 
comparable with the projected ratio of 13  from our data 
(Fig. 9), within the uncertainties of this system. 
A further consequence of prolonged Tac survival due to 
any cause (renal failure or antibody binding) will be to alter 
the  normal  spatial  distributions  of Tac  in  the  body.  For 
sTac  generated  extravascularly,  the  rapidity  of the  renal 
clearance mechanisms  in  contact with  the  vascular  com- 
partment will generate a steep gradient in the unperturbed 
setting, with substantially higher levels in the extravascular 
compartment versus  that  in  blood.  With  the  longer sur- 
vival, however, this gradient of Tac concentration in vivo 
is substantially flattened, yielding a marked increase in the 
normally low  physiologic  ratio  of Tac  in  serum  to  Tac 
body burden. 
An unexpected outcome of these studies of Tac metabo- 
lism was the apparent faster catabolism of Tac-in-complex 
versus  antibody-in-complex.  Our  analysis  (see  Results) 
eliminated the hypothesis that the shorter tl/2  was  due to 
the rapid clearance of the dissociated, free portion of Tac 
(13") in the equilibrium. This left us with the more surpris- 
ing second alternative:  that  catabolic activities may attack 
one part of the anti-TaclTac complex, Tac, while sparing 
the  other  part,  anti-Tac.  One  speculation  may  be  war- 
ranted on the nature of  such a process which can selectively 
"extract" Tac from this high affinity complex. This phe- 
nomenon suggests  features shared by normal IgG catabo- 
lism and intestinal and placental IgG transport (51-53). To 
explain the acceleration of IgG catabolism with higher se- 
rum IgG, Brambell et al. (51) proposed that IgG taken into 
pinocytic vacuoles is bound to specific tgG receptors (FcR) 
that redirect its transport to the circulation. Once the puta- 
tive "protection receptors" are saturated, the remainder of 
the IgG is subject to unrestricted lysosomal catabolism for a 
net acceleration at high serum concentrations. 
The Brambell hypothesis may be adapted to the present 
setting. We propose that anti-Tac]Tac complexes are in- 
ternalized  to  acidified  vesicles  as  normal  IgG.  Anti-Tac 
bound  to  the  protection  FcR  is  returned  to  circulation, 
whereas  Tac  released from the  complex in  the  vesicle is 
catabolized, thus yielding faster net catabolic rates for circu- 
lating antigen-in-complex than antibody-in-complex. That 
vesicles may be thus topologically "divided" was  demon- 
strated with transferrin and horseradish peroxidase (HR.P): 
both colocalize in early endosomes, but transferrin returns 
to the surface bound to its receptor whereas HRP proceeds 
to the late endosomes and lysosomes (54).  Endosomes are 
characterized by reduced pH  that  is  thought  to  promote 
ligand-receptor dissociation (54), whereas the relevant Fc- 
FcR interactions are acid enhanced (53,  55), thereby plau- 
sibly enabling IgG recycling to the surface via bound FcR, 
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be "chewed" out of antibody by endosomal proteases  (56). 
Normal  IgG  catabolism  appears  to  be  widespread,  with 
highest relative activity in liver and spleen (20, 57). Because 
these sites  are rich in cells bearing FcR (including a major 
nonhematopoietic FcR [55]), this catabolic mechanism has 
plausibility in the context of these other data. The new fea- 
ture  of this  proposal  is  that  it joins  these  recent  in  vitro 
concepts to bulk metabolic observations in whole animals. 
In any case, the metabolism of Tac in the presence of anti- 
body may introduce a new, slower catabolic route for the 
antigen  which  supplants  preexisting  renal  and  nonrenal 
mechanisms. Other monomeric antigen-antibody complexes 
may be expected to experience similar fates. 
It is a necessary consequence of these kinetic studies that 
prolongation  of antigen  survival  will  result  in  increased 
steady state  sTac levels during antibody therapy unless the 
mechanisms of Tac production are directly and rapidly sup- 
pressed  by the  therapy  itsels  We know from other work 
that  Tac  production  can  persist  at  high levels  for at  least 
several  days into  therapy,  even in patients  who ultimately 
undergo complete remission, during which serum Tac lev- 
els may increase  10-fold or more (our unpublished results). 
In the  case of anti-Tac,  the  antibody blocks  IL-2 binding 
by Tac, and higher Tac levels due to antibody complexing 
will not increase its ability to capture ligand. Moreover, the 
affinity for IL2 by Tac in isolation is so low  (/~  108 M -l) 
that it would require Tac concentrations of the order of 10 
p~M to compete 50% with high affinity receptor (o~/), an 
inconceivable  concentration  since  the  highest  antibody 
concentration  in  therapy  would probably  not  exceed  0.3 
I~M  (50  p~g/ml).  (The  highest  serum  sTac level we  have 
observed is 0.05 p~M; our unpublished results.) There is ac- 
cordingly no  evidence  to  suggest  an independent  regula- 
tory role for the soluble form of this molecule in vitro or in 
vivo.  On the  other hand,  other cytokines or cytokine re- 
ceptors to which therapy might be  directed  could lead to 
increased biologic activity in vivo if the  active  site  is  not 
also blocked by the antibody, as recently most convincingly 
shown for anti-IL3, anti-IL4, and anti-IL7 antibodies that cap- 
ture and stabilize these proteins in active configurations (58). 
The role of sTac and other soluble molecules as a surro- 
gate for body burden  of tumor or activated T  cells  can be 
interpreted in the context of these results. Among ATL pa- 
tients,  there  is  a  general  correspondence  between  disease 
volume  and  sTac  levels  (our  unpublished  results),  as  also 
observed  for hairy  cell  leukemia,  another  Tac-expressing 
malignancies (15). Higher sTac levels should correlate with 
more shedding, but where individuals differ in Tac expres- 
sion or shedding rate, as noted here, this correlation weak- 
ens  at  the  level  of estimating  numbers  of Tac-expressing 
cells.  Donor 1 in Table  1 underwent remission during her 
treatment with antibody directed at TM-Tac on the surface 
of her malignant cells.  Subsequently, she experienced a re- 
lapse  of her  disease,  at  which  time  her  cells  exhibited  a 
nearly  identical  pattern  of Tac  expression  and  shedding. 
For this  individual,  the  in vitro  results  suggest that  serum 
sTac could reasonably be used as a measure  of her disease. 
sTac may thus  be  useful  as  a  serum  marker for many pa- 
tients  in the same sense that elevated  CEA concentrations 
are a marker for recurrence in colon cancer and other ma- 
lignancies, but in which individuals  are known to differ in 
the relative expression of the marker (59). 
Although the plasma level of the soluble form of Tac and 
other  cell  surface  molecules  is  a  reasonable  correlate  of 
physiologic condition or disease expression, its use must be 
tempered  with  knowledge  of the  biology of the  protein. 
We  showed  that  antibody  binding  markedly  inhibits  the 
metabolism  of sTac  with  a  corresponding increase  in  the 
serum concentration.  In addition,  as is true for other small 
molecules,  Tac is catabolized chiefly by the kidney.  Thus, 
it is concluded that serum concentrations of soluble antigen 
in renal failure  or during antibody therapy cannot be used 
as a surrogate measure of tumor burden or T  cell activation 
because receptor levels will both increase and differentially 
redistribute  as  a  consequence  of prolonged survival,  in the 
absence of changes in soluble antigen production. 
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1600  Metabolism of Tac Note  added in proof" The  receptors for  lgG  protection  (FcRp)  [51,53]  and  intestinal transport  (FclLn) 
[52,53,55],  both described by Brambell, were recently shown to be identical using mice knocked-out for the 
receptor light chain (Junghans,  R.P.  and C.L. Anderson, manuscript submitted for publication). In such 
mice, IgG protection and differential catabolism were both lost, yielding clearance of antibody- and antigen- 
in-complex at the same accelerated rate as albumin. This confirms the central role of the FcRp to the differ- 
ential catabolism mechanism, as postulated in this article. 
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